Dodds Ashley Elizabeth S, Alexander Barbara D
Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Drugs Today (Barc). 2005 Jun;41(6):393-400. doi: 10.1358/dot.2005.41.6.898145.
Invasive fungal infections are occurring with increasing frequency secondary to medical advances in the areas of transplantation, cancer management and autoimmune diseases. Unfortunately, the currently available antifungal armamentarium does not meet the increasing needs of managing infection in these complex patient populations. Posaconazole, a new triazole antifungal agent, is being investigated for its role in treating serious infections due to yeasts and molds. This new drug offers an expanded spectrum of activity over other members of its class. In addition to potent activity against fluconazole-resistant Candida and refractory cases of aspergillosis, posaconazole demonstrates activity against Zygomycetes. Posaconazole is a well-tolerated agent that offers a diminished toxicity profile compared with other currently marketed systemic antifungal agents. Clinical success rates thus far have been promising, although the exact role of this agent in treating and preventing invasive fungal infections is yet to be determined.
随着移植、癌症治疗和自身免疫性疾病等领域的医学进步，侵袭性真菌感染的发生率正日益增加。不幸的是，目前可用的抗真菌药物并不满足这些复杂患者群体日益增长的感染管理需求。泊沙康唑是一种新型三唑类抗真菌药物，正在研究其在治疗由酵母菌和霉菌引起的严重感染中的作用。这种新药与其同类其他药物相比，具有更广泛的活性谱。除了对氟康唑耐药的念珠菌和难治性曲霉病病例具有强效活性外，泊沙康唑还对接合菌具有活性。泊沙康唑是一种耐受性良好的药物，与目前市场上销售的其他全身性抗真菌药物相比，其毒性较低。尽管该药物在治疗和预防侵袭性真菌感染中的确切作用尚未确定，但迄今为止临床成功率很有前景。
